Physician profile
Inna Kigel
NPI 1235210956
$15,359.46
in general payments reported to CMS, 2019-2025
56 companies · $1,557 in 2025
The $1,557 reported for 2025 was more than what 93% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,373 · 2020: $1,682 · 2021: $2,961 · 2022: $2,336 · 2023: $2,406 · 2024: $2,045 · 2025: $1,557.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,966 · Education: $41.52.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,965.79 |
| Education | $41.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,126.31 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,788.08 | 2019-2025 | Jardiance, Synjardy, Tradjenta |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,206.75 | 2019-2025 | Xifaxan, Trulance |
| Astrazeneca Pharmaceuticals Lp | $1,135.49 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Kowa Pharmaceuticals America, INC. | $909.00 | 2019-2024 | Seglentis, Livalo, Zoryve |
| Scilex Pharmaceuticals INC. | $908.02 | 2019-2025 | Ztlido |
| Glaxosmithkline, LLC. | $820.34 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Novo Nordisk INC | $422.95 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $389.03 | 2019-2024 | Repatha, Prolia, Evenity |
| Lilly USA, LLC | $381.48 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Ardelyx, INC. | $366.32 | 2022-2024 | Ibsrela |
| Horizon Therapeutics Plc | $356.62 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $346.91 | 2019-2021 | |
| Sunovion Pharmaceuticals INC. | $265.09 | 2019-2022 | |
| Gilead Sciences, INC. | $256.02 | 2019-2025 |
Show all 56 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Inna Kigel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.